0000950170-24-025943.txt : 20240305 0000950170-24-025943.hdr.sgml : 20240305 20240305161642 ACCESSION NUMBER: 0000950170-24-025943 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240303 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hughes Eric A CENTRAL INDEX KEY: 0001938678 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-16174 FILM NUMBER: 24720635 MAIL ADDRESS: STREET 1: C/O TEVA STREET 2: 5 BASEL STREET, P.O. BOX 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 4951033 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000818686 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 124 DVORA HANEVI'A ST. CITY: TEL AVIV STATE: L3 ZIP: 6944020 BUSINESS PHONE: 972 (3) 914-8213 MAIL ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 124 DVORA HANEVI'A ST. CITY: TEL AVIV STATE: L3 ZIP: 6944020 4 1 ownership.xml 4 X0508 4 2024-03-03 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0001938678 Hughes Eric A C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A ST., TEL AVIV L3 6944020 ISRAEL false true false false See "Remarks" true Ordinary Shares 2024-03-03 4 M false 24900 A 24900 D Ordinary Shares 2024-03-04 4 S false 8045 13.3373 D 16855 D Restricted Share Units 2024-03-03 4 M false 24900 0 D Ordinary Shares 24900 74701 D Restricted Share Units 2024-03-04 4 A false 93005 0 A Ordinary Shares 93005 93005 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027. Restricted share units were granted on March 4, 2024, with 23,251 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 23,252 vesting on March 4, 2028. Executive Vice President, Global R&D and Chief Medical Officer /s/ Dov Bergwerk as attorney-in-fact for Eric Hughes 2024-03-05